The first case of hepatitis B patients was completed in phase A clinical trial of PD-L1 antibody ASC22II.a.

Guide: ASC22 is the world's first (first-in-class) subsoccuper-injectable PD-L1 antibody.
, Hangzhou, August 17, 2020 /USC/ -- Goliath Pharmaceutical Co., Ltd. (Hong Kong Stock Exchange Code: 1672) today announced that asC22II.a clinical trials have completed the first case of hepatitis B patients.
ASC22 is the world's first (first-in-class) subsoccupic injection of PD-L1 antibodies.
ASC22 (Nvoli monoantigen) Phase IIa clinical trial is a single-dose incremental study using three subdermal dosage doses (0.3, 1.0 and 2.5 mg/kg) to explore the safety and effectiveness of ASC22 (Nvoli monoanti) in patients with chronic hepatitis B (ClinicalTrials.gov Registration No. NCT04465890).
In chronic hepatitis B virus infection, T-cell depletion is an important factor of immune tolerance, and blocking the PD-1/PD-L1 path can effectively improve the specific killing T-cell function, which is expected to make chronic hepatitis B patients achieve clinical cure.
currently, there are about 257 million people infected with hepatitis B virus worldwide and about 70 million people infected in China.
"very excited that the asC22 (Nvoli monoanti) clinical trial has completed the first case of hepatitis B patients. "As the world's first PD-L1 antibody that promises a clinical cure for chronic hepatitis B, ASC22 (Nvoli monoantimmune) can be injected to provide patients with a convenient way to deliver drugs, and is expected to be used as a cornerstone drug for a variety of treatment options, in association with candidate drugs developed in-house or other industry leaders," said Dr. Jinxuan Wu, Founder, Chairman and CEO of
.
, chairman of Corning Jerry's, said: "We look forward to the clinical results of the safety and efficacy of Nvoli monoantigen in patients with HBV.
its unique immune mechanism, Nvoli monoantigen is likely to promote HBV-specific immune responses, producing serum transformation and giving patients hope of a cure.
the same concept may be applied in other patients with long-term viral infections.
advantages and values of the safety and convenience of Nvoli monodermal drug use are best reflected in the treatment of chronic diseases.
"About ASC22ASC22 (KN035, Nvoli monotherapy, Cory obtained its rights from Corning Jerry for the treatment of all viral diseases) is a PD-L1 monoclonal antibody that can be used for subliminal injection, with subsolutional injection, stable at room temperature and other advantages, thereby improving patient drug compliance, improving patient quality of life, and achieving the goal of long-term management of chronic diseases such as chronic hepatitis B.
January 14, 2019, Goliath and Suzhou Corning Jerry Biotech Co., Ltd. signed a strategic cooperation agreement in the field of hepatitis B and other viral diseases.
, there are now more than 1000 patients in the Nvoli monoantigen group, showing good safety and efficacy in multiple tumor adaptations.
Corning-Jerry is preparing to submit a new drug application for MSI-H.
.